Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging–Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study

Michael Ahdoot, Aurash Naser‐Tavakolian, Cheyenne Williams, Michael Daneshvar, Patrick Gomella, S Mallavarapu, Minhaj Siddiqui, Michael Nazmifar, Joanna H. Shih, Barış Türkbey, Bradford J. Wood, Peter A. PintoThe Journal of Urology 2025 · DOI

Abstract

Given an approximate doubling in grade group <u>≥</u> 3 cancer detection on combined biopsy with rising PSAD intervals, clinicians may consider PSAD in risk stratifying men at high risk of clinically significant prostate cancer. Clinicians may consider omitting systematic biopsy for targeted biopsy of MRI-visible lesions in patients with PSAD <u>≥</u> 0.2 ng/mL/cm<sup>3</sup>, as systematic biopsy results in low rates of additional clinically significant cancer detection.
BibTeX
@article{ahdoot2025prostate,
  author = {Michael Ahdoot and Aurash Naser‐Tavakolian and Michael Ahdoot and Cheyenne Williams and Michael Daneshvar and Patrick Gomella and S Mallavarapu and Minhaj Siddiqui and Michael Nazmifar and Joanna H. Shih and Barış Türkbey and Bradford J. Wood and Peter A. Pinto},
  title = {{Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging–Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study}},
  journal = {The Journal of Urology},
  year = {2025},
  doi = {10.1097/ju.0000000000004480},
}

Loading related content...

Figure